60 Degrees Pharmaceuticals Inc (SXTP) - News Archive

Tremendous strides are being made in eradicating Babesiosis, a tick-borne illness that affects both humans and canines, due to the pioneering efforts of 60 Degrees Pharmaceuticals (60 Degrees Pharma, Nasdaq: SXTP). The...

Introduction In a significant development for 60 Degrees Pharmaceuticals (60P), the United States Food and Drug Administration (FDA) has communicated its intention to respond to the company s trial protocol submission f...

In a significant move towards advancing global healthcare, 60 Degrees Pharmaceuticals has recently announced its sponsorship of pre-clinical studies on the potential use of tafenoquine in combating Candida spp infection...

In a move aimed at advancing their mission of combating malaria and further expanding their research endeavors, 60 Degrees Pharmaceuticals (60P) has announced a public offering pricing of $2.4 million. The funds generat...

In what could potentially emerge as a game-changer in the medical and biotech sphere, 60 Degrees Pharma has recently announced plans for a pivotal study of tafenoquine in hospitalized patients suffering from babesiosis....

Babesiosis, an emerging tick-borne disease, poses a growing public health concern in several regions. With limited treatment options currently available, there is an urgent need for effective therapies to combat this de...